- Open Access
A modified human ELISPOT assay to detect specific responses to primary tumor cell targets
© Malyguine et al; licensee BioMed Central Ltd. 2004
- Received: 23 December 2003
- Accepted: 29 March 2004
- Published: 29 March 2004
The desired outcome of cancer vaccination is to induce a potent T cell response which can specifically recognize and eliminate autologous tumor cells in vivo. Accordingly, immunological assays that demonstrate recognition of native tumor cells (tumor-specific) may be more clinically relevant than assays that demonstrate recognition of tumor protein or peptide (antigen-specific).
Towards this goal, we adapted the IFN-γ ELISPOT assay to measure immune responses against autologous primary tumor cells in vaccinated cancer patients. As a model system to develop the assay, we utilized peripheral blood mononuclear cells (PBMC) directly isolated from follicular lymphoma patients vaccinated with tumor-derived idiotype protein.
After optimizing several variables, we demonstrated that the modified IFN-γ ELISPOT assay could be used to reliably and reproducibly determine the tumor-reactive T cell frequency in the PBMC of these patients. The precursor frequency of tumor-reactive T cells was significantly higher in the postvaccine PBMC, compared with prevaccine samples in all patients tested. Furthermore, the specificity of these T cells was established by the lack of reactivity against autologous normal B cells.
These results demonstrate the feasibility of quantitating tumor-specific T cell responses when autologous, primary tumor cells are available as targets.
- Peripheral Blood Mononuclear Cell
- Cancer Vaccine
- ELISPOT Assay
- Autologous Tumor Cell
- Primary Tumor Cell
Active specific immunotherapy is a promising but investigational modality in the management of cancer patients. Currently, several different cancer vaccine formulations such as peptides, proteins, antigen-pulsed dendritic cells, whole tumor cells, etc. in combination with various adjuvants and carriers are being evaluated in clinical trials [1–3]. To determine the optimal cancer vaccine strategy, a surrogate immunological end-point that correlates with clinical outcome needs to be defined since it would facilitate the rapid comparison of these various formulations.
The clinical efficacy of cancer vaccines is likely to depend on several factors. Firstly, the induced T cells should recognize tumor antigens that are naturally processed and presented in the context of MHC class I and class II molecules on the surface of the tumor. Hence, an immunological assay that demonstrates recognition of native tumor (tumor-specific) may be a more clinically relevant assay to assess T cell responses following cancer vaccination, compared with assays that demonstrate recognition of tumor protein or peptide presented on appropriate antigen-presenting cells (antigen-specific). Secondly, the functional quality and the magnitude of the induced anti-tumor T cell responses are critical for the successful eradication of cancer. Therefore, it is conceivable that an immunological assay that directly measures both the function and frequency of the induced tumor-specific T cells could potentially serve as a surrogate end-point for cancer vaccine trials.
Traditional immunological assays such as ELISA, proliferation and cytotoxicity assays can detect immune responses in vaccinated patients but are unable to quantitate individual reactive cells. In contrast, novel assays such as ELISPOT assay, intracellular cytokine assay and tetramer assay can quantitate the frequency of antigen-specific T cells. Of these, the ELISPOT assay is the most sensitive with a general limit of detection of 1 × 105 PBMC when tested with tumor antigens . The assay detects locally secreted cytokine molecules by means of antibody-coated membranes to capture the secreted cytokine derived from the productive interaction of the effector cell and its target cell. The assay has gained increasing popularity, especially as a surrogate measure for cytotoxic T lymphocyte (CTL) responses because it is simple, reliable, sensitive and quantitative [5, 6]. However, the ELISPOT assay has been primarily used for the detection of T cell responses against vaccine components by using peptide or protein pulsed antigen-presenting cells as surrogate T cell targets [7–9]. Demonstration of reactivity to vaccine components does not necessarily equate to recognition and elimination of tumor cells.
Here, we report the development of a modified IFN-γ ELISPOT assay for the direct quantitation of T cell responses against autologous primary tumor cells. To develop the assay, we used follicular lymphoma patients vaccinated with tumor-derived idiotype (Id) protein as a model, since we have previously shown that Id vaccination induces tumor-specific T cell responses in these patients .
After obtaining signed informed consent, patients with Stage III or IV follicular center cell lymphoma grade 1 or grade 2 were enrolled on this investigational review board-approved clinical trial. All patients underwent a lymph node biopsy prior to starting treatment to obtain tissue for vaccine production. The lymph node specimen was processed into a single cell suspension and cryopreserved. Patients were initially treated uniformly with a chemotherapy regimen as described previously .
Vaccine formulation and administration
Tumor immunoglobulin protein, Id, was isolated from each patient's tumor by heterohybridoma fusion . The appropriate fusions were identified by comparing the Ig VH CDR3 sequences of the fusions with the patient's tumor. The Id was incorporated into liposomes along with recombinant human IL-2 as described previously . Each dose of the vaccine was formulated on a per ml basis with 2 mg of the patient-specific tumor-derived Id protein, 4 × 106 IU of recombinant human IL-2 and 160 mg of dimyristoylphosphatidylcholine lipid (DMPC, Biomira USA Inc., NJ) that was used to generate liposomes. Approximately six months after the completion of the chemotherapy, all patients were administered five doses of the vaccine subcutaneously at months 0, 1, 2, 3 and 5.
Peripheral Blood Mononuclear Cells
Blood samples were obtained from patients at various time points before and after vaccination. Peripheral blood mononuclear cells (PBMC) were isolated by density gradient separation with Ficoll Isopaque (ICN Biomedicals Inc., Aurora, OH) and cryopreserved for immunological assays. Pre- and postvaccine PBMC were thawed, washed and resuspended to a concentration of 1–3 × 106 cells/ml in RPMI 1640 medium (Invitrogen Corp, Carlsbad, CA), supplemented with 5% FBS (Hyclone, Logan, Utah), 1 mM sodium pyruvate (BioWhittaker, Walkersville, MD), 20 mM HEPES buffer (Invitrogen), 50 μM β-mercaptoethanol (Sigma, St. Louis, MO), 2 mM L-glutamine, 100 U/ml penicillin and 100 μg/ml streptomycin (Invitrogen) (complete medium). Five ml of the cell suspensions were plated into each well of 6 well plates (Corning, Inc. Corning, NY) and rested overnight at 37°C, 5% CO2. The next day, PBMC were harvested, washed and cell viability was assessed by trypan blue prior to use in the ELISPOT assay.
Activation of tumor cells and normal B cells
Cryopreserved cells from the lymph node biopsy specimen were enriched for tumor cells by depletion of T cells with CD3 microbeads over a magnetic column (Miltenyi Biotec, Auburn, CA) using the manufacturer's protocol. Autologous normal B cells were isolated from PBMC by magnetic cell separation method using the B Cell Isolation Kit (Miltenyi Biotec) according to the manufacturer's protocol. The purity of the isolated tumor and normal B cells was >95%. Tumor cells and normal B cells were activated for 3 days with 800 ng/ml of recombinant human soluble CD40 ligand trimer (sCD40Lt, Amgen, Thousand Oaks, CA) and recombinant human IL-4 (2 ng/ml) (Peprotech, Rocky Hill, NJ). Activated tumor cells and normal B cells were harvested and washed prior to co-culture with PBMC in the ELISPOT assay.
IFN-γ Enzyme-linked immunospot (ELISPOT) assay
MultiScreen-IP opaque 96-well plates (High Protein Binding Immobilon-P membrane, Millipore, Bedford, MA) were coated overnight at room temperature with 50 μl/well of 20 μg/ml mouse anti-human IFN-γ mAb (BioSource, Camarillo, CA) in DPBS (Invitrogen). After overnight incubation, the plates were washed three times with 200 μl DPBS/well and blocked with 200 μl/well of RPMI 1640, 10% human AB serum (Mediatech, Herndon, VA), 25 mM Hepes, 2 mM L-glutamine, 100 U/ml penicillin and 100 μg/ml streptomycin (Invitrogen) for 2 h at 37°C, 5% CO2. Harvested effectors were added to the plates in triplicates at 1 × 105 cells/well with either culture medium alone or with 2 × 105 cells/well sCD40Lt activated autologous tumor cells and cultured for 48 h at 37°C, 5% CO2. The plates were washed manually 6 times with 200 μl/well of DPBS/0.05% Tween. 50 μl/well of 2 μg/ml mouse anti-human IFN-γ-biotinylated mAb (BD Pharmingen, San Diego, Ca) in DPBS/1%BSA/0.05% Tween was added and the plates were incubated for 2 h at room temperature. Plates were manually washed 4 times with DPBS and 50 μl/well of streptavidin HRP (BD Pharmingen) diluted 1:2000 in DPBS/1% BSA was added for 1 h at room temperature. The plates were washed a final 4 times with DPBS. Spots were visualized by adding 100 μl/well of TrueBlue™ Peroxidase Substrate (KPL, Gaithersburg, MD) for 2 min. Plates were scanned and counted using the ImmunoSpot analyzer (Cellular Technology, Ltd., Cleveland, OH) to determine the number of spots/well. The precursor frequency of tumor-specific T cells was determined by subtracting the background spots in tumor alone and PBMC alone from the number of spots seen in response to tumor cells.
Statistical analysis was performed using Student's t-test for paired mean values and Pearson correlation coefficient (R2).
Optimization of tumor IFN-γ ELISPOT assay
Summary of assay conditions that were tested and selected for the autologous tumor IFN-γ ELISPOT assay
Selected for assay
Clear vs. Opaque
Targets (tumor cells)
sCD40Lt stimulated vs. non-stimulated
Overnight cultured vs 2 h cultured
Overnight cultured cells
100:100, 100:200, 100:300K
200:100, 200:200, 200:300K
Incubation time of assay
24 and 48 hours
5% and 10% HuAB vs. 5% and 10% FBS
Substrate Detection System
AEC, TrueBlue™, and BCIP
Opaque plates were optimal for analysis of IFN-γ spots
Opaque and clear plastic versions of MultiScreen-IP ELISPOT plates were compared to facilitate optimal spot analysis using the ImmunoSpot analyzing system. The opaque version was most advantageous for ELISPOT enumeration. The opaque plastic precluded light-refraction from the reader's light source and therefore eliminated alterations in background color of individual wells that interfered with the ability to correctly enumerate spots. The ImmunoSpot analyzing system was able to auto-center opaque, but not the clear plastic plates, thereby facilitated automated analysis.
sCD40Lt activated tumor cells enhanced cytokine production by T cells
Activation of B cell tumor cells with sCD40Lt upregulated various costimulatory molecules and MHC class I and class II molecules on the surface of tumor cells associated with enhanced antigen presenting capability [ and Neelapu et al., manuscript submitted]. Our pilot experiments indicated that activation of tumor cells with sCD40Lt markedly enhanced the sensitivity of the ELISPOT assay by increasing the IFN-γ production by responding T cells as compared to unmodified tumor cells (data not shown). We have therefore used sCD40Lt activated tumor cells as stimulators to evaluate T cell responses in this assay.
Resting PBMC overnight improved the reactivity of effector cells
Effector to tumor cell ratio
Longer assay incubation time detected higher number of tumor-reactive T cells
10% Human AB serum was optimal for culture medium
Substrate detection system
IFN-γ spots produced by pre- and postvaccine PBMC using the optimized assay
Based on preliminary testing, the protocol described in the materials and methods was established as optimal (Table 1). Triplicate wells demonstrating the IFN-γ spots produced by pre- and postvaccine PBMC analyzed in parallel from a representative patient are shown in Figure 6. A significantly higher number of IFN-γ spots were detected in the postvaccine PBMC as compared to the prevaccine sample (p < 0.001).
Reproducibility of the tumor IFN-γ ELISPOT assay
Specificity of the tumor-reactive T cell responses
Our data demonstrate that the ELISPOT assay could be easily adapted to reliably and reproducibly determine the precursor frequency of tumor-specific T cells in follicular lymphoma patients immunized with an autologous tumor-derived Id vaccine. We have also been able to use a modification (5 day tumor activation, 72 h incubation) of this assay to quantitate the tumor-specific T cell responses in mantle cell lymphoma patients vaccinated with Id (data not shown). Thus, this assay fulfilled our stated objectives for a clinically relevant immunological assay by demonstrating that it could functionally (IFN-γ production) and quantitatively assess the T cell responses induced by a cancer vaccine against autologous primary tumor cells.
As opposed to the traditional antigen-specific assays that assess immune responses against vaccine components (peptides or proteins), tumor-specific immunological assays in addition to being more clinically relevant can have several advantages. Firstly, tumor-specific assays can potentially detect both CD4+ and CD8+ T cell responses since endogenous antigens are presented by both MHC class I molecules as well as MHC class II molecules [[13–15] and Neelapu et al., manuscript submitted]. In contrast, antigen-specific (protein) assays detect mostly CD4+ T cell responses since the soluble exogenous antigen is predominantly processed in the endosomal pathway and presented on MHC class II molecules. Secondly, tumor-specific assays can be used in patients with any HLA phenotype unlike peptide assays that are usually restricted to a single HLA phenotype (e.g. HLA-A*0201) depending on the binding affinity of the peptide. Thirdly, tumor-specific assays allow monitoring of patients when whole or lysed tumor cells are used as the immunogen and the tumor-specific antigens have not been defined. Finally, tumor recognition assays potentially enable the detection of immune responses against the immunogen as well as other antigens not represented in the vaccine. For instance, they can detect immune responses against cryptic epitopes that may develop by epitope spreading, secondary to the inflammatory response initiated by T cells specific against the immunogen [16, 17].
A probable limitation for tumor recognition assays is the availability of tumor cells. While primary tumor cells are easily accessible for some cancers (e.g. lymphoma, leukemia, myeloma, melanoma), they may not be generally accessible for certain other cancers (e.g. breast cancer, renal cell cancer). When available, it may be feasible to adapt the IFN-γ ELISPOT assay for the quantitative assessment of T cell responses against primary tumor cells as a preferable alternative to antigen-specific assays. Such quantitative tumor-specific immunological assays need to be eventually evaluated in large clinical trials to determine their validity as surrogate end-points for clinical efficacy of cancer vaccines.
We adapted the IFN-γ ELISPOT assay to directly measure immune responses against autologous primary tumor cells in vaccinated cancer patients. We demonstrated that the modified IFN-γ ELISPOT assay could be used to reliably and reproducibly determine the tumor-reactive T cell frequency in the PBMC of these patients when sCD40Lt activated tumor cells were used as targets. The precursor frequency of tumor-reactive T cells was significantly higher in the postvaccine PBMC, compared with prevaccine samples in all patients tested. Furthermore, the specificity of these T cells was established by the lack of reactivity against autologous normal B cells. These results demonstrate the feasibility of quantitating tumor-specific T cell responses when autologous, primary tumor cells are available as targets.
We thank Amgen for generously providing the sCD40Lt and Biomira USA Inc., for manufacturing the vaccine. Contract NO1-CO-12400 Funded by the National Cancer Institute.
The Content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, not does mention of trade names, commercial products, or organisations imply endorsement by the U.S Government.
- Rosenberg S: Progress in human tumor immunology and immunotherapy. Nature. 2001, 411: 380-384. 10.1038/35077246.View ArticlePubMedGoogle Scholar
- Wang R, Rosenberg S: Human tumor antigens for cancer vaccine development. Immunol Rev. 1999, 170: 85-100.View ArticlePubMedGoogle Scholar
- Kwak L: Translational development of active immunotherapy for hematologic malignancies. Semin Oncol. 2003, 30 (3 Suppl 8): 17-22. 10.1016/S0093-7754(03)00232-X.View ArticlePubMedGoogle Scholar
- Keilholz U, Weber J, Finke J, Gabrilovich D, Kast W, Disis M, Kirkwood J, Scheibenbogen C, Schlom J, Maino V, Lyerly H, Lee P, Storkus W, Marincola F, Worobec A, Atkins M: Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother. 2002, 25: 97-138. 10.1097/00002371-200203000-00001.View ArticlePubMedGoogle Scholar
- Whiteside T: Immunologic monitoring of clinical trials in patients with cancer: technology versus common sense. Immunol Invest. 2000, 29: 149-162.View ArticlePubMedGoogle Scholar
- Schmittel A, Keilholz U, Thiel E, Scheibenbogen C: Quantification of tumor-specific T lymphocytes with the ELISPOT assay. J Immunother. 2000, 23: 289-295. 10.1097/00002371-200005000-00001.View ArticlePubMedGoogle Scholar
- Peterson A, Harlin H, Gajewski T: Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma. J Clin Oncol. 2003, 21: 2342-2348. 10.1200/JCO.2003.12.144.View ArticlePubMedGoogle Scholar
- Asai T, Storkus W, Mueller-Berghaus J, Knapp W, DeLeo A, Chikamatsu K, Whiteside T: In vitro generated cytolytic T lymphocytes reactive against head and neck cancer recognize multiple epitopes presented by HLA-A2, including peptides derived from the p53 and MDM-2 proteins. Cancer Immun. 2002, 2: 3-PubMedGoogle Scholar
- Meidenbauer N, Harris D, Spitler L, Whiteside T: Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer. Prostate. 2000, 43: 88-100. 10.1002/(SICI)1097-0045(20000501)43:2<88::AID-PROS3>3.0.CO;2-G.View ArticlePubMedGoogle Scholar
- Bendandi M, Gocke C, Kobrin C, Benko F, Sternas L, Pennington R, Watson T, Reynolds C, Gause B, Duffy P, Jaffe E, Creekmore S, Longo D, Kwak L: Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med. 1999, 5: 1171-1177. 10.1038/13928.View ArticlePubMedGoogle Scholar
- Kwak L, Pennington R, Boni L, Ochoa A, Robb R, Popescu M: Cutting Edge: Liposomal formulation of a self lymphoma antigen induces potent protective anti-tumor immunity. J Immunol. 1998, 160: 3637-3461.PubMedGoogle Scholar
- Schultze J, Cardoso A, Freeman G, Seamon M, Daley J, Pinkus G, Gribben J, Nadler L: Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity. Proc Natl Acad Sci USA. 1995, 92: 8200-8204.PubMed CentralView ArticlePubMedGoogle Scholar
- Nuchtern J, Biddison W, Klausner R: Class II MHC molecules can use the endogenous pathway of antigen presentation. Nature. 1990, 343: 74-76. 10.1038/343074a0.View ArticlePubMedGoogle Scholar
- Sant A: Endogenous antigen presentation by MHC class II molecules. Immunol Res. 1994, 13: 253-267.View ArticlePubMedGoogle Scholar
- Maecker H, Dunn H, Suni M, Khatamzas E, Pitcher C, Bunde T, Persaud N, Trigona W, Fu T, Sinclair E, Bredt B, McCune J, Maino V, Kern F, Picker L: Use of overlapping peptide mixtures as antigens for cytokine flow cytometry. J Immunol Methods. 2001, 255: 27-40. 10.1016/S0022-1759(01)00416-1.View ArticlePubMedGoogle Scholar
- Lally K, Mocellin S, Ohnmacht G, Nielsen M, Bettinotti M, Panelli M, Monsurro V, Marincola F: Unmasking cryptic epitopes after loss of immunodominant tumor antigen expression through epitope spreading. Int J Cancer. 2001, 93: 841-847. 10.1002/ijc.1420.View ArticlePubMedGoogle Scholar
- Disis M, Gooley T, Rinn K, Davis D, Piepkorn M, Cheever M, Knutson K, Schiffman K: Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol. 2002, 20: 2624-2632. 10.1200/JCO.2002.06.171.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.